Trial Profile
Anlotinib-based Combination as First-line Treatment in Advanced Non-small Cell Lung Cancer: a Single Center, Three Arms and Exploratory Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Erlotinib (Primary) ; Sintilimab (Primary) ; Carboplatin; Gemcitabine; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Jun 2021 Status changed from recruiting to completed, according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 31 Jan 2021 Results (n=22) presented at the 2020 World Conference on Lung Cancer.